Novartis (NYSE:NVS) has inked a deal with the biopharma Carisma Therapeutics focused on the production of human epidermal growth factor receptor 2 (HER2)-targeted chimeric antigen receptor macrophages (CAR-M) to potentially treat solid tumors.Carisma is headquartered in Philadelphia.
As part of the deal, Carisma will shift manufacturing to a Novartis cell therapy site in Morris Plains, New Jersey.
Novartis anticipates clinical manufacturing to begin in 2023.
Get the full story from our sister site, Drug Discovery & Development.
Tell Us What You Think!